Skip to main content
UPB
NASDAQ Life Sciences

Upstream Bio Reports Widened Q1 Net Loss, Caps COPD Trial Enrollment, Advances Phase 3 Programs

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Negative
Importance info
7
Price
$9.04
Mkt Cap
$487.059M
52W Low
$7.25
52W High
$33.68
52W Position info
25% above low
Off High info
73% below high
Rel. Volume info
0.4× avg
Market data snapshot near publication time

UPB sits 25% above its 52-week low of $7.25 on light trading volume (0.4× avg).

Summary

Upstream Bio announced Q1 2026 financial results, reporting a widened net loss due to higher R&D, while also updating on its clinical pipeline, including capping enrollment in its Phase 2 COPD trial and advancing two programs to Phase 3.


Key Events · Earnings and Guidance · UPB

  • Widened Net Loss in Q1 2026

    The company reported a net loss of $40.6 million for the first quarter ended March 31, 2026, compared to a net loss of $27.3 million for the same period in 2025, primarily due to increased R&D expenses.

  • Increased R&D Expenses

    Research and development expenses rose to $36.6 million in Q1 2026 from $25.8 million in Q1 2025, driven by clinical and manufacturing costs for verekitug programs.

  • Capped Enrollment in Phase 2 COPD Trial

    Upstream Bio will cap further enrollment in its Phase 2 VENTURE trial for COPD, with data now expected in the second half of 2027, indicating a potential re-evaluation or delay for this program.

  • Advancing Phase 3 Programs

    The company is rapidly advancing its Phase 3 programs for verekitug in severe asthma and chronic rhinosinusitis with nasal polyps (CRSwNP), with End-of-Phase 2 FDA meetings planned for mid-2026 and Phase 3 initiations expected in Q1 2027.


Analysis · UPB · Life Sciences

Upstream Bio reported a significantly widened net loss for Q1 2026, primarily driven by increased research and development expenses for its verekitug programs. While the company maintains a cash runway through 2027, the decision to cap enrollment and delay data for the Phase 2 COPD trial introduces uncertainty for that program. However, the company is actively progressing its severe asthma and CRSwNP programs towards Phase 3 initiation in Q1 2027, with FDA meetings planned for mid-2026.

How filings like this one have moved

In the 30 days to Nov 15, 2026, 37.5% of the 3713 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, UPB was trading at $9.04 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $487.1M. The 52-week trading range was $7.25 to $33.68. This filing was assessed with negative market sentiment and an importance score of 7 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

UPB - Latest Insights

UPB
Sep 01, 2026, 7:05 AM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $6.70
Real-time Price: $2.57 info
Change: -$4.13 (-62%) info
Market Cap: $141.413M info
UPB
Sep 01, 2026, 7:00 AM EDT
Source: GlobeNewswire
Importance Score:
8
Price at Filing: $6.70
Real-time Price: $2.57 info
Change: -$4.13 (-62%) info
Market Cap: $141.413M info
UPB
Aug 11, 2026, 7:10 AM EDT
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $7.26
Real-time Price: $2.57 info
Change: -$4.69 (-65%) info
Market Cap: $141.413M info
UPB
Aug 11, 2026, 7:05 AM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $7.26
Real-time Price: $2.57 info
Change: -$4.69 (-65%) info
Market Cap: $141.413M info
UPB
Jun 14, 2026, 10:00 AM EDT
Source: GlobeNewswire
Importance Score:
8
Price at Filing: $6.36
Real-time Price: $2.57 info
Change: -$3.79 (-60%) info
Market Cap: $141.413M info